Skip to main content
. Author manuscript; available in PMC: 2012 Sep 20.
Published in final edited form as: Biochemistry. 2011 Aug 26;50(37):8057–8066. doi: 10.1021/bi200573t

Table 1.

Drug resistance profile of wild-type and mutant BCRP

MX SN-38 Dox Rho123

IC50 (nM) RR IC50 (nM) RR IC50 (nM) RR IC50 (nM) RR
pcDNA5/FRT 5.6 ± 0.8 - 1.7 ± 0.1 - 33.1 ± 2.2 - 4218 ± 400.0 -
Wild-type BCRP 51.5 ± 8.5 9.2 30.3 ± 2.0 17.8 40.9 ± 6.7 1.2 4446 ± 261.5 1.1
P392A 24.6 ± 3.8 4.4* 13.1 ± 1.0 7.7* 34.8 ± 1.7 1.1 5326 ± 414.1 1.3
P480A 69.4 ± 10.5 12.4 37.8 ± 1.5 22.2 29.0 ± 4.0 0.9 5107 ± 272.7 1.2
P485A 38.5 ± 7.0 6.9 15.9 ± 2.6 9.4* 41.8 ± 5.3 1.3 3237 ± 199.5 0.8
P501A 40.9 ± 14.6 7.3 27.5 ± 2.4 16.2 23.2 ± 3.8 0.7 4480 ± 816.4 1.1
P574A 49.6 ± 12.5 8.9 32.5 ± 2.6 19.1 29.6 ± 3.5 0.9 5320 ± 419.8 1.3
P623A 68.4 ± 14.4 12.2 36.8 ± 2.8 21.6 37.0 ± 8.8 1.1 3302 ± 388.1 0.8

The relative resistance (RR) values represent the relative levels of resistance of the mutants compared to wild-type BCRP, and were calculated by dividing the IC50 values of wild-type and mutant BCRP by the IC50 values of the vector control. Wild-type and mutant BCRP did not confer resistance to Dox or Rho123. The IC50 values shown are means ± S.D. of three experiments. Differences in IC50 values between wild-type and mutant BCRP are statistically significant:

*

p < 0.05 by the Student’s t- test. Since the expression levels of wild-type and mutant BCRP were comparable, we did not normalize the resistance data to BCRP protein expression.